Evolus Partners with IBSA for Exclusive U.S. Rights to Market-Leading Profhilo® Skin Quality Injectable
EOLS sits 77% above its 52-week low of $3.86.
Summary
Evolus entered an exclusive licensing deal with IBSA to bring Profhilo®, a leading European skin quality injectable, to the U.S. market, expanding its aesthetic portfolio.
Key Events · M&A and Partnerships · EOLS
-
Exclusive U.S. Licensing Agreement
Evolus secured exclusive rights from IBSA to develop and commercialize Profhilo®, a hyaluronic acid product for skin quality, in the United States.
-
Expansion into Skin Quality Market
This partnership expands Evolus' injectable portfolio into the rapidly growing and underpenetrated skin quality segment, complementing its existing neurotoxin and dermal filler products.
-
Capital-Efficient Deal Structure
The agreement requires no upfront payments or milestone payments, with economics structured through a transfer-price model designed to support gross margins.
-
Market-Leading Product
Profhilo® is a market-leading injectable in Europe with over 4.8 million treatments administered globally, providing a strong foundation for U.S. market entry.
Analysis · EOLS · Life Sciences
Evolus has secured exclusive U.S. rights to Profhilo®, a globally recognized and market-leading injectable for skin quality. This strategic partnership expands Evolus' portfolio into a high-growth aesthetic segment with a proven product, positioning the company for long-term revenue diversification and growth without requiring upfront payments.
How filings like this one have moved
In the 30 days to Sep 19, 2026, 34.9% of the 1133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EOLS was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $457M. The 52-week trading range was $3.86 to $10.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.